Compare FGBI & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | PYXS |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 141.3M |
| IPO Year | 2014 | 2021 |
| Metric | FGBI | PYXS |
|---|---|---|
| Price | $8.84 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 14.0K | ★ 848.7K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | $7,043.98 |
| P/E Ratio | $28.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.31 | $1.03 |
| 52 Week High | $11.02 | $5.55 |
| Indicator | FGBI | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 52.01 |
| Support Level | $8.24 | $2.95 |
| Resistance Level | $8.86 | $3.45 |
| Average True Range (ATR) | 0.28 | 0.32 |
| MACD | 0.09 | -0.03 |
| Stochastic Oscillator | 93.20 | 29.86 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.